OCT derived secondary outcomes
hyperplasia
HYPERPLASIA
Strut coverage with neo-intimal thickness > 40 µm did not differ between groups: exenatide group 79.4% (35–95%) vs. 64% (34.3–90.5%) in the control group (p = 0.589). The percentage of relevant malapposition (i.e. > 300 µm) was low and not significantly different between treatment groups: exenatide group 0.4% (0.8%) and 1.4% (4.2%) in the control group (p = 0.368). The mean area of neo-intimal hyperplasia was 1.3 mm